PDCD1 and malignant pleural mesothelioma: Our rationale for selecting statins was supported by a recent clinical study, exhibiting that statins are associated with improved antitumor efficacy of anti-PD-1 therapy in malignant pleural mesothelioma and advanced nonsmall-cell lung cancer patients [7].